Sreedhar Mandayam retweeted
Phase 2a study of readthrough therapy in nonsense mutation #Alport syndrome jci.org/articles/view/208623
Sreedhar Mandayam retweeted
🌟 Fantastic talk by Sean Barbour about the use of risk prediction tools in clinical trials!
Visit 'GNpredict. com' to access evidence-based prediction tools 💥
@Tobias_B_Huber @utmbhealth
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
Sreedhar Mandayam retweeted
Initiation of Apixaban Versus Warfarin in Patients With Kidney Failure on Hemodialysis With Newly Diagnosed Atrial Fibrillation: A Target Trial Emulation
bit.ly/4yWE5NI
@winkeldoc @MontezRath @LParkerGregg1 @Khairallah_P @taraichang

ALT Time to Discontinuation among Persons who Initiated Apixaban versus Warfarin. Note: Apixaban users (in red) and warfarin users (in blue) had filled their first apixaban/warfarin prescription within 30 days from their new diagnosis with atrial fibrillation. Continued use was present when a subsequent apixaban/warfarin prescription was filled within no more than 7 days after the most recent supply was exhausted. If no refill occurred, 7 days were added to the most recent days’ supply. Apixaban/warfarin use also ended when a prescription for a different OAC was filled. We used the Aalen-Johnson estimator to graph the cumulative incidence function for both exposure groups
Sreedhar Mandayam retweeted
B- and plasma cell-targeting therapies for podocytopathies: state of the art and the New Gaslini protocol academic.oup.com/ckj/article…
Sreedhar Mandayam retweeted
sadly unaffordable - the last column is estimated annual costs …and we have no idea when they should/can be stopped?
more on the nephjc blog nephjc.com/news/2026/10/21/k…
#KidneyWK
Sreedhar Mandayam retweeted
What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
doi.org/10.1093/ndt/gfaf144
Sreedhar Mandayam retweeted
🩸 Introducing DIALYSIS TROUBLESHOOTING
From intradialytic hypotension and machine alarms to vascular access complications, PD problems and CRRT troubleshooting — we're covering it all!
📚 18 Weeks | 18 Topics | 1 Post Every Week
Sreedhar Mandayam retweeted
Cancer patients waste away partly because their own fat starts burning itself. The signal that starts it is not a cytokine. It is iron. Could this insight lead to a drug to prevent cachexia in cancer patients?
doi.org/10.1038/s43018-026-0…
Sreedhar Mandayam retweeted
Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time? ovid.com/jnls/jasn/fulltext/… @ISGDtweets @asnpublications @GlomCon @SabineKaram6 @BoudhabhayI
Sreedhar Mandayam retweeted
It’s Nephrology Nurses Week! 💙 We’re celebrating the nephrology nurses who bring expertise, compassion and dedication to every stage of kidney care.
Thank you for all you do to advance kidney care and support the patients and families who rely on you.
Love it
Dr. Suman Biswas (@amateursuman) once of Amateur Transplants performs 'Placebo' ('Let it Go') at The BMJ Medics' Revue 2026.
2/2 (see profile feed for first half).
1
56
Sreedhar Mandayam retweeted
Sunday Spotlight💫: Presenting the most comprehensive proteomic map of systemic #Lupus erythematosus to date (>6000 proteins)! doi.org/10.1172/jci.insight.…
Geoffrey H. D. Leung @gleung23 James E. Peters @lab_peters & team @imperialcollege report potential therapeutic targets, biomarkers, and autoantibody-linked proteomic signatures in #SLE, providing a basis for precision medicine.
The figure shows SLE disease activity–associated proteins correlated with IFNL1.
@MedResFdn
Sreedhar Mandayam retweeted
Renowned renal pathologist, @SethiRenalPath , on stage for the @glomcon Helmut Rennke Endowed Lectureship
#GlomConHawaii
Sreedhar Mandayam retweeted
Women’s health and life planning by all star panelists @anuja_java @Srmanday @BetterCallSeeth @silvishah
Excellent talk by @erin_vaughan_ 🫶👌🏻
#GlomConHawaii
Advancing cancer detection and treatment using longitudinal routine clinical data: Cell cell.com/cell/fulltext/S0092…
83
Sreedhar Mandayam retweeted
Congratulations @NeehaZaidi @DanielHaldarMD @DrLizJaffee and team! This is the 1st study to demonstrate the feasibility of mutant KRAS targeted vaccine - not in established #PancreaticCancer - but in HIGH RISK individuals, with persistent T cells ~2years!
aacrjournals.org/cancerdisco…
Sreedhar Mandayam retweeted
Thank you to Prolato Clinical Research and Sunnyside Super Neighborhood 71 for inviting me to their Summer Health Fair! It was so great to see community members and constituents come together to learn about these resources so that we can take care of ourselves and each other.
Wonderful to see State Representative Lauren Ashley Simmons at the Sunnyside center health fair. We screened over 50 high risk patients for Apol1 #Apol1, #Sanofi, #BoehringerIngelheim




































